FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org August 19, 2009 (10.1056/NEJMe0905763)

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Mok, T. S. Related Article by Rosell, R. PubMed Citation

The concept underlying much of cancer therapy is that patients with specific types and stages of cancer should be treated according to standardized, predetermined protocols. However, recent advances in drug development, pharmacogenomics, and the molecular characterization of tumors — including genomewide RNA expression, DNA copy-number and sequence analyses, and microRNA and proteomic profiling — have the potential to allow individualized selection of treatment as determined by the characteristics of the patient and the tumor.

In principle, targeted therapies attack cancer-cell–specific attributes that are essential for growth or survival ("oncogene addiction") and avoid the potentially severe side effects of conventional cytotoxic . . . [Full Text of this Article]

Source Information

From the Hamon Center for Therapeutic Oncology Research, Simmons Cancer Center, and the Department of Pathology, University of Texas Southwestern Medical Center, Dallas.

This article (10.1056/NEJMe0905763) was published on August 19, 2009, at NEJM.org.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.